Radiolabelled peptides and monoclonal antibodies are an emerging class of radiopharmaceuticals for imaging inflammation with clinical implications for several chronic inflammatory disorders for diagnosis, therapy decision making and follow up. In the last decades, a number of novel monoclonal antibodies and peptides have been introduced for the treatment of different inflammatory disorders and also labelled with a variety of radionuclides depending upon the specific applications, diagnostic or therapeutic, by using direct or indirect methods. These radiopharmaceuticals bind to their targets with high affinity and specificity and therefore have an excellent diagnostic potential for the imaging of patients with chronic inflammatory diseases. In this review article we describe the characteristics of peptides, cytokines and monoclonal antibodies with a particular emphasis on their role in therapy decision making and follow up in different inflammatory diseases.

Radiolabelled peptides and monoclonal antibodies for therapy decision making in inflammatory diseases / G., Malviya; Signore, Alberto; Lagana', Bruno; R. A., Dierckx. - In: CURRENT PHARMACEUTICAL DESIGN. - ISSN 1381-6128. - 14:24(2008), pp. 2401-2414. [10.2174/138161208785777414]

Radiolabelled peptides and monoclonal antibodies for therapy decision making in inflammatory diseases

SIGNORE, Alberto;LAGANA', Bruno;
2008

Abstract

Radiolabelled peptides and monoclonal antibodies are an emerging class of radiopharmaceuticals for imaging inflammation with clinical implications for several chronic inflammatory disorders for diagnosis, therapy decision making and follow up. In the last decades, a number of novel monoclonal antibodies and peptides have been introduced for the treatment of different inflammatory disorders and also labelled with a variety of radionuclides depending upon the specific applications, diagnostic or therapeutic, by using direct or indirect methods. These radiopharmaceuticals bind to their targets with high affinity and specificity and therefore have an excellent diagnostic potential for the imaging of patients with chronic inflammatory diseases. In this review article we describe the characteristics of peptides, cytokines and monoclonal antibodies with a particular emphasis on their role in therapy decision making and follow up in different inflammatory diseases.
2008
cytokines; diagnosis; inflammation; molecular imaging; monoclonal antibodies; nuclear medicine; radiopharmaceuticals; therapy decision making
01 Pubblicazione su rivista::01a Articolo in rivista
Radiolabelled peptides and monoclonal antibodies for therapy decision making in inflammatory diseases / G., Malviya; Signore, Alberto; Lagana', Bruno; R. A., Dierckx. - In: CURRENT PHARMACEUTICAL DESIGN. - ISSN 1381-6128. - 14:24(2008), pp. 2401-2414. [10.2174/138161208785777414]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/230262
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 18
social impact